Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy

被引:0
|
作者
Tsavaris, N [1 ]
Mylonakis, N [1 ]
Bacoyiannis, C [1 ]
Kosmas, C [1 ]
Kalergis, G [1 ]
Iakovidis, V [1 ]
Tzaninis, D [1 ]
Kosmidis, P [1 ]
机构
[1] Metaxa Canc Hosp, Dept Med Oncol 2, Piraeus 18537, Greece
关键词
antiemetic activity; metoclopramide; cisplatin;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Some clinical parameters play a role in developing effective antiemetic therapy. In the present study, 310 patients entered and 301 were evaluable. They received cisplatin based combination chemotherapy (100 mg/m(2)), with antiemetic therapy based in metoclopramide, at a standard dose and schedule (2 mg/kg in 5 doses). Patient characteristics such as age, sex, performance status (Karnofsky), site of primary tumor, weight loss >15%, previous chemotherapy, previous radiotherapy, history of vomiting during pregnancy, additional drugs (dexamethasone, alprazolam), in the antiemetic regimen were included in the evaluation. We also studied the manifestation of anxiety and depression and the presence of psychosocial problems related to therapy, evaluated them with specific psychological indexes modified for our study. We evaluated incidence of vomiting, retches, and nausea, with several scales. We distinguished three groups of factors influencing nausea and vomiting. Factors that predicted for increased nausea and vomiting was gender (women), stress and age (younger patients experienced more prolonged duration and higher grades of nausea). The addition of alprazolam (a sedative drug) and dexamethasone, was associated with decreased incidence of nausea and vomiting. The weight loss (increased nausea and decreased vomiting control according to Gralla's scale). Previous chemotherapy decreased the number of patients without nausea and vomiting control according to Gralla's scale. Patients with previous radiotherapy presented an increased grade of nausea. Patients with head and neck cancer presented less nausea with shorter duration, less frequent episodes of vomiting. Patients with ovarian cancer presented increased mean number of retches. In conclusion, despite difficulties in assessing nausea and vomiting among clinical trials, several factors, especially stress, gender, weight loss, additional drugs (corticosteroids and sedatives) may play an important role in modulating the antiemetic response.
引用
收藏
页码:1147 / 1155
页数:9
相关论文
共 50 条
  • [21] SIDE-EFFECTS OF METOCLOPRAMIDE AS AN ANTIEMETIC IN CHILDHOOD-CANCER CHEMOTHERAPY
    TERRIN, BN
    MCWILLIAMS, NB
    MAURER, HM
    JOURNAL OF PEDIATRICS, 1984, 104 (01): : 138 - 140
  • [22] ANTIEMETIC EFFECT AND PHARMACOKINETICS OF HIGH-DOSE METOCLOPRAMIDE IN CANCER-PATIENTS TREATED WITH CISPLATIN-CONTAINING CHEMOTHERAPY REGIMENS
    HAVSTEEN, H
    NIELSEN, H
    KJAER, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (01) : 33 - 40
  • [23] 5-DRUG ANTIEMETIC COMBINATION FOR CISPLATIN CHEMOTHERAPY
    SRIDHAR, KS
    HUSSEIN, AM
    HILSENBECK, S
    CAIRNS, V
    CANCER INVESTIGATION, 1992, 10 (03) : 191 - 199
  • [24] ONDANSETRON - A NEW ANTIEMETIC FOR PATIENTS RECEIVING CISPLATIN CHEMOTHERAPY
    EINHORN, LH
    NAGY, C
    WERNER, K
    FINN, AL
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (04) : 731 - 735
  • [25] ANTIEMETIC REGIMENS IN OUTPATIENTS RECEIVING CISPLATIN AND NON-CISPLATIN CHEMOTHERAPY - A RANDOMIZED TRIAL COMPARING HIGH-DOSE METOCLOPRAMIDE PLUS METHYLPREDNISOLONE WITH AND WITHOUT LORAZEPAM
    BARON, MG
    CHACON, JI
    GIRON, CG
    GALLEGO, AO
    DEPAREDES, MLG
    FELIU, J
    ZAMORA, P
    HERRANZ, C
    GARRIDO, P
    ARTAL, A
    ACTA ONCOLOGICA, 1991, 30 (05) : 623 - 627
  • [26] EFFECT OF DIPHENHYDRAMINE ON THE ANTIEMETIC ACTION OF METOCLOPRAMIDE AGAINST CISPLATIN-INDUCED EMESIS IN DOGS
    SMITH, WL
    JACKSON, CB
    SANCILIO, LF
    ALPHIN, RS
    CANCER TREATMENT REPORTS, 1986, 70 (07): : 934 - 935
  • [27] HIGH-DOSE METOCLOPRAMIDE AS AN ANTIEMETIC IN PATIENTS RECEIVING CIS-PLATINUM-BASED COMBINATION CHEMOTHERAPY
    GEZ, E
    CATANE, R
    PFAU, L
    BIRAN, S
    GYNECOLOGIC ONCOLOGY, 1985, 21 (01) : 18 - 22
  • [28] THE ANTIEMETIC ACTIVITY OF DROPERIDOL ADMINISTERED BY INTRAMUSCULAR INJECTION DURING CISPLATIN CHEMOTHERAPY - A PILOT-STUDY
    CERSOSIMO, RJ
    BROMER, R
    HOFFER, S
    WELCH, J
    ABRAHAMSON, M
    HONG, WK
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1985, 19 (02): : 118 - 121
  • [29] ANTIEMETIC PROPHYLAXIS WITH HIGH-DOSE METOCLOPRAMIDE OR LORAZEPAM IN VOMITING INDUCED BY CHEMOTHERAPY
    BOWCOCK, SJ
    STOCKDALE, AD
    BOLTON, JAR
    KANG, AA
    RETSAS, S
    BRITISH MEDICAL JOURNAL, 1984, 288 (6434): : 1879 - 1879
  • [30] Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy
    Yang, Chan-Keng
    Wu, Chiao-En
    Liaw, Chuang-Chi
    BIOMEDICAL JOURNAL, 2016, 39 (01) : 60 - 66